Tymlos (abaloparatide), for the postmenopausal osteoporosis, has a label update on the MOA, now reads as: "Once-daily...abaloparatide stimulates new bone formation on trabecular & cortical bone surfaces by stimulation of osteoblastic activity." https://t.co/AC9JvtmIdZ